6. (Amended) The pharmaceutical material of claim 2 in which the active pharmaceutical ingredient is included within the crystal at a concentration of about 0.001 to 1 weight percent based on the weight of the crystal including the active pharmaceutical ingredient.

11. (Amended) The invention of claim 1 in which, for each crystal, the active pharmaceutical ingredient is included within the crystal in a growth-sector specific orientation.

12. (Amended) The invention of claim 1 and further comprising a pharmaceutically-acceptable adjuvant selected from the group consisting of excipients, diluents, carriers and mixtures thereof.

13. (Amended) The invention of claim 1 in which the active pharmaceutical ingredient is a biopharmaceutical.

14. (Amended) The invention of claim 1 in which the crystal lattice component is selected from the group consisting of: sucrose, lactose, trehalose, maltose, galactose, sorbose, mannitol, lactitol, sorbitol, glycine, alanine, lysine, arginine, ascorbic acid, nicotinamide, thiamine, adenine, pyridoxine hydrochloride, caffeic acid, vanillic acid, ferulic acid, benzoate, sorbate, methyl paraben, sodium ascorbate, sodium saccharine, potassium citrate, zinc, calcium, and any derivatives, salt forms, or mixtures thereof.